Physician profile
Ryan T Bowes
NPI 1811351687
$6,673.70
in general payments reported to CMS, 2019-2025
44 companies · $47.76 in 2025
The $47.76 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $1,662 · 2023: $2,755 · 2024: $1,804 · 2025: $47.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,606.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,610.62 | 2022-2024 | |
| Mdd US Operations, LLC | $602.21 | 2022-2024 | Apokyn, Apokyn, Gocovri |
| Pfizer INC. | $425.79 | 2023-2024 | |
| Ucb, INC. | $354.03 | 2023-2024 | Fintepla, Briviact, Rystiggo |
| Emd Serono, INC. | $253.55 | 2021-2024 | Mavenclad |
| Lilly USA, LLC | $252.74 | 2022-2024 | Emgality, Reyvow, Amyvid |
| Csl Behring | $245.97 | 2021-2024 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $239.75 | 2021-2024 | Austedo Xr, Ajovy, Austedo |
| Biogen, INC. | $229.33 | 2021-2024 | Vumerity |
| Sk Life Science, INC. | $205.31 | 2023-2024 | |
| Acorda Therapeutics, INC | $189.78 | 2022-2023 | Ampyra, Inbrija |
| Amneal Pharmaceuticals LLC | $180.25 | 2022-2023 | Rytary |
| Amgen INC. | $144.35 | 2021-2023 | Aimovig |
| Eisai INC. | $134.06 | 2021-2024 | |
| Tg Therapeutics, INC. | $132.75 | 2023-2024 | Briumvi |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Bowes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.